ASO Author Reflections: Androgen Receptor as a Potential Biomarker and Therapeutic Target for Immunotherapy in ER-positive/HER2-negative Breast Cancer
Year: 2026
Type: article
Source: Annals of Surgical Oncology
Institutions: Roswell Park Comprehensive Cancer Center, Osaka Medical and Pharmaceutical University, Hirosaki University, University of Rochester Medicine, University of Rochester, Tokyo Medical University, University at Buffalo, State University of New York, Niigata University, Yokohama City University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
Awards: ホルモン陽性乳癌への免疫チェックポイント阻害剤の適応拡大～薬剤併用で切り拓く～, G2348382760, A Novel Strategy for Breast Cancer Treatment with T-DXd: Targeting HER2 Conversion Induced by Eribulin, G3350520333, G3841121202, G3981001102, G4776147864, Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer, Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
OpenAlex ID: W7223667111